PATIENTS & FAMILIES

Ready to improve lives

We’re ready to help families affected by pediatric cancer. From day one and every day after. And, if we see opportunities to help adults with cancer or others with our advanced therapies, we’ll take those on with the same passion and commitment.

If you’d like to know more about our work, take a look at our therapies in development and our ongoing clinical trials. Or sign up for news alerts and get in touch.

PATIENTS & FAMILIES

Ready to improve lives

We’re ready to help families affected by pediatric cancer. From day one and every day after. And, if we see opportunities to help adults with cancer or others with our advanced therapies, we’ll take those on with the same passion and commitment.

If you’d like to know more about our work, take a look at our therapies in development and our ongoing clinical trials. Or sign up for news alerts and get in touch.

A note to the community

On June 12, 2022, Day One announced positive initial data from the first subset of participants in our ongoing pivotal Phase 2 FIREFLY-1 trial of tovorafenib (DAY101) in patients with relapsed pediatric low-grade glioma, or pLGG. Please see our press release and corporate presentation for more details.

On behalf of everyone at Day One, we thank the patients who have participated in the FIREFLY-1 study and their families, without whom this advancement toward a potential new targeted therapy for pLGG would not be possible.

We also thank the pediatric cancer patient advocacy community for your partnership and support as we move forward in developing potential new therapies for children with cancer.

Finding support

We understand the challenges of a cancer diagnosis, and we are here to help. We encourage you to connect with the many community resources available to families like yours through these organizations.

Our future is dedicated to their future.

View our pipeline